|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online September 29, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
In this issue |
The blood-brain barrier (BBB) stops most peptides entering the CNS and represents a significant obstacle to therapies for neurological disorders. Identifying carriers that could transport peptide-based drugs across the endothelial cells of the BBB is therefore an important goal but so far largely unattained. Weihong Pan and co-workers now reveal that a chaperone protein called RAP that normally facilitates folding and trafficking of low-density lipoprotein (LDL) receptors might be the answer (see p. 5071). Using 125I-labelled RAP, they show that the chaperone efficiently crosses the BBB both in brain-perfusion assays and in vivo when injected intravenously. They then dissect the transport mechanism, demonstrating that passage of RAP across epithelial monolayers in vitro is promoted by megalin - a protein implicated in transcytosis across several types of epithelial cell. At 39 kDa, RAP is large enough to serve as a transporter for smaller molecules. Moreover, its transport across the BBB is significantly more efficient than that of two other potential carriers, transferrin and melanotransferrin. RAP thus has exciting potential as a vehicle for peptide-based drugs that target the CNS.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
Related articles in JCS:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||